ESC 365 - Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: a FIDELITY analysis

ESC Professional Premium Access

Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: a FIDELITY analysis

Session: Novel targets and treatments for heart diseases and diabetes

Topic: Aldosterone Antagonists

Event: ESC Congress 2023

Congress Presentation

Add to my library

4 more presentations in this session

State-of-the-art lecture on novel targets and treatments for heart diseases and diabetes

Speaker: Professor J. Pernow (Stockholm, SE)

Biochemical profiles and risk of cardiovascular events in patients withType 2 Diabetes: implications for choice of novel antihyperglycemic therapy

Speaker: Doctor M. Elmegaard (Copenhagen, DK)

GLP1 receptor agonists exhibit antioxidant and anti-inflammatory properties in human heart tissue via the canonical GLP1 receptor expression through a AMPK-mediated pathway

Speaker: Doctor E. Cordeanu (Strasbourg, FR)

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis

Speaker: Doctor R. Mentz (Durham, US)

Access the full session

Novel targets and treatments for heart diseases and diabetes

Speakers: Professor J. Pernow, Doctor M. Elmegaard, Doctor E. Cordeanu, Doctor R. Mentz

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources